BioCryst Pharmaceuticals (BCRX) reported Q4 adjusted loss Monday of $0.13 per diluted share, narrower from a loss of $0.28 a year earlier.
Four analysts polled by FactSet expected loss of $0.06.
Revenue for the quarter ended Dec. 31 was $131.5 million, up from $93.4 million a year earlier. Analysts surveyed by FactSet expected $130.1 million.
BioCryst Pharmaceuticals now expects full year 2025 total revenue of $560 million and $575 million, compared with the previous forecast of $540 million to $560 million. Analysts surveyed by FactSet expect $548.9 million.
Shares were down 3% in premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。